Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI-based Maintenance Therapy in Advanced Biliary Tract Cancer
NCT07269158Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib, venadaparib and SLC-3010 in biliary tract cancer (BTC) (4 arms), sponsored by Yonsei University. Primary endpoints: Recommended Phase II Dose at 4 years and Progression-Free Survival at 4 years. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lenvatinibvenadaparibSLC-3010
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07269158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269158.